#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #bispecific antibody

ADC Therapeutics Unveils Positive Data from LOTIS-7 Clinical Trial

ADC Therapeutics SA (NYSE: ADCT), known for its pioneering efforts in the field of antibody-drug conjugates (ADCs), has recently announced encouraging preliminary results from their Phase 1b LOTIS-7 clinical trial. This study evaluates the efficacy and safety of ZYNLONTA® when combined with the bispecific antibody glofitamab (COLUMVI™) in patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

In a press release on December 11, 2024, Dr. Mohamed Zaki, Chief Medical Officer at ADC Therapeutics, expressed excitement over the robust results. The initial data suggests that the combination therapy may lead to significant clinical benefits, implying that the interaction between these two potent therapies could result in added effectiveness without overlapping toxicities.

Key Findings from the Trial

Clinical Efficacy

LOTIS-7 is an ongoing trial that consists of both dose escalation and expansion phases and aims to assess patients with r/r B-cell non-Hodgkin lymphoma (B-NHL). As of November 20, 2024, 29 patients had been evaluated, offering a glimpse into the treatment's potential.

• - Overall Response Rate (ORR): An impressive 94% of evaluable patients showed a best overall response (17 out of 18) according to Lugano criteria.
• - Complete Response Rate (CRR): Achieved a notable 72% rate (13 out of 18 patients), with 12 of these patients maintaining complete response by the cutoff date.
• - Among the 150µg/kg dose arm, the results were even more promising with a 100% ORR.

Safety Profile

Safety analysis reflects that the combination treatment is generally well tolerated. No dose-limiting toxicities (DLTs) were reported across all patients. Adverse events recorded included:

• - Neutropenia: 24%
• - Lymphopenia: 7%
• - Hypokalemia: 7%

Furthermore, some patients experienced Cytokine Release Syndrome (CRS) of Grade 1 or 2, which was manageable with standard care.

Moving Forward

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, views these results as potentially positioning ZYNLONTA plus glofitamab as a leading option in a competitive market. The data also paves the way for the next steps in the trial, including completing enrollment in the expansion phase scheduled for early 2025. Engagement with regulatory authorities to discuss future plans will also follow as more comprehensive data becomes available.

Conclusion

As ADC Therapeutics continues its clinical journey with LOTIS-7, the initial findings are poised to potentially reshape treatment strategies for relapsed DLBCL. With upcoming conference calls scheduled for detailed presentations, stakeholders and patients alike are keenly watching this promising development in oncology.

For patients battling r/r DLBCL, the results from LOTIS-7 signify hope, as innovative therapeutic strategies like ZYNLONTA combined with glofitamab could herald a new era in treatment efficacy and safety. Detailed updates will undoubtedly follow, as ADC Therapeutics remains committed to advancing its groundbreaking ADC technology against challenging hematologic malignancies.